Context Therapeutics Inc. (NASDAQ:CNTX) Short Interest Up 99.1% in June

Context Therapeutics Inc. (NASDAQ:CNTX) was the recipient of a large growth in short interest in June. As of June 30th, there was short interest totalling 2,230,000 shares, a growth of 99.1% from the June 15th total of 1,120,000 shares. Based on an average trading volume of 703,800 shares, the days-to-cover ratio is presently 3.2 days. Currently, 3.4% of the shares of the stock are short sold.

Context Therapeutics Stock Performance

NASDAQ CNTX remained flat at $2.02 during trading on Friday. The company’s stock had a trading volume of 36,302 shares, compared to its average volume of 371,609. The firm’s fifty day moving average price is $1.92 and its 200 day moving average price is $1.45. Context Therapeutics has a 12-month low of $0.77 and a 12-month high of $2.24.

Context Therapeutics (NASDAQ:CNTX) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.15. On average, sell-side analysts predict that Context Therapeutics will post -0.36 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on CNTX shares. HC Wainwright reiterated a “buy” rating and set a $5.00 target price on shares of Context Therapeutics in a research report on Wednesday. Maxim Group increased their price objective on Context Therapeutics from $4.00 to $10.00 and gave the company a “buy” rating in a research report on Thursday, May 9th. Piper Sandler assumed coverage on Context Therapeutics in a research note on Thursday, May 16th. They issued an “overweight” rating and a $4.50 target price for the company. Finally, Piper Sandler Companies initiated coverage on shares of Context Therapeutics in a research note on Thursday, May 16th. They issued an “overweight” rating and a $4.50 price objective on the stock.

Institutional Trading of Context Therapeutics

A hedge fund recently bought a new stake in Context Therapeutics stock. Opaleye Management Inc. bought a new position in shares of Context Therapeutics Inc. (NASDAQ:CNTX) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 975,000 shares of the company’s stock, valued at approximately $1,102,000. Opaleye Management Inc. owned about 6.11% of Context Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.